NSE: VIMTALABS · BSE: 524394 · ISIN INE579C01029
Vimta Labs Limited stock analysis
Vimta Labs Limited ranks #632 in the TickerSutra evidence-ranked universe with a score of 62/100 and 95% data confidence. The latest captured fundamentals show ROCE of 25.2%, quarterly sales growth of 11.8% and quarterly profit growth of 11.4%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 25.2%
- Low debt/equity of 0.01×
- Strong CFO/EBITDA of 1.04×
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- No calculated threshold risk in the current snapshot.
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹276cr | ₹80cr | ₹41cr | 29.0% |
| 2023 | ₹315cr | ₹94cr | ₹47cr | 30.0% |
| 2024 | ₹289cr | ₹94cr | ₹41cr | 33.0% |
| 2025 | ₹344cr | ₹122cr | ₹67cr | 35.0% |
| 2026 | ₹407cr | ₹142cr | ₹78cr | 35.0% |
| TTM | ₹419cr | ₹145cr | ₹80cr | 35.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
MANAGEMENT COMMENTARY
Signals from filed documents
Positive enquiry trends, healthy demand visibility and deeper customer engagement across markets reinforce our confidence in the growth prospects of the business. At Vimta Labs Limited July 20, 2026 Page 4 of 16 the same time, we remain firmly committed to prudent capital allocation, strong governance, regulatory compliance and industry-leading quality standards. In conclusion, despite near-term softness in select se
The Company’s experienced senior management and scientific leadership further strengthen execution resilience and strategic agility. Taken together, these strengths provide a strong foundation for sustained growth, deeper client engagement, improved operating leverage, and a positive medium- to long-term outlook. 2.1 OUR STRENGTHS & STRATEGIES Your Company’s strengths have been its human resources, processes, partner
The GMP , GLP and GCP compliant services have been successfully audited several times during the year by customers, regulatory agencies, accrediting and certifying bodies. In addition to its established pre-clinical research, clinical research, and analytical capabilities, VIMTA has strengthened its biopharmaceutical services platform through backward integration across the biologics and peptides drug development con
In addition, the 15.19% year-on-year increase in India's FY '26-'27 defense budget allocation is expected to support higher demand for testing and qualification services for defense electronics and related systems, further strengthening the growth outlook for our Electronics and Electrical Testing business. On the demand front, enquiry levels continued to improve across both domestic and international markets. We are
This reflects the structural strength of our business model, the depth of our operating discipline and our continued focus on efficiency and execution excellence. Looking ahead, we remain confident about the medium- to long-term opportunities across our service portfolio. Positive enquiry trends, healthy demand visibility and deeper customer engagement across markets reinforce our confidence in the growth prospects o
In addition, we have strengthened our customer feedback mechanisms through stringent review systems and appropriate preventive actions. Financial risks: Vimta makes continuous investments in capacity expansion, market reach and new business streams. These investments are based on good business judgement through market study, backed by strong planning and risk mitigation measures.
India has introduced significant regulatory reforms through the New Drugs and Clinical Trials (Second Amendment) Rules, 2026, aimed at simplifying and accelerating export-focused bioavailability and bioequivalence (BA/BE) studies. The amendment introduces a “prior intimation” route, allowing eligible low-risk BA/BE studies to commence upon online submission and acknowledgment, eliminating the need for prior regulator
Typically, we tend to use the depreciation amount of the last fiscal for the current year capex. And the second question is on customer concentration. Would you be able to give us some color on what is the contribution of top 5 customers and top 10 customers?
(Amount in INR millions, unless otherwise stated) Material Accounting Policies and explanatory notes forming part of the Financial Statements 163 36th Annual Report, 2025 - 26 42 Capital management and ratios The Company’s objectives when managing capital are to safeguard their ability to continue as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders, an
c) Official news releases The Quarterly Results, Shareholding Pattern, official press releases, investor presentations, analysis and other relevant information are made available on the Company’s website at www.vimta.com as well as on the websites of the Stock Exchanges where the Company’s shares are listed. d) Presentations made to institutional investors or to the analysts During the financial year under review, ei
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…